A Study of CEA-Targeted CAR-T Therapy in Patients With CEA-Positive Advanced Solid Tumors

This study tests a type of immune cell therapy called CEA-targeted CAR-T cells in patients with advanced cancers (including lung and breast cancer) whose tumors express a protein called CEA (carcinoembryonic antigen). Patients' own immune cells are collected, engineered to recognize CEA, and then infused back to fight the cancer. **You may be eligible if...** - You are 18 or older - You have confirmed advanced, metastatic, or recurrent solid tumor (including non-small cell lung cancer or breast cancer) - Your tumor tests positive for CEA - Your cancer has progressed after at least two prior lines of standard treatment - You have at least one measurable tumor - Your general health (ECOG 0–2) and organ function meet study requirements - Your expected survival is at least 12 weeks **You may NOT be eligible if...** - You have active or uncontrolled cancer spread to the brain or spinal fluid - You have a serious heart condition (Class III–IV heart failure, recent heart attack) - You have an active autoimmune disease or are on long-term immune-suppressing medications - You have active HIV, hepatitis B or C, or syphilis - You are pregnant or breastfeeding - You received another clinical trial treatment within the past 4 weeks Talk to your doctor to see if this trial is right for you.